Compared with mono-antibodies, the soluble receptor has a lower risk for tuberculosis and general infections. But as to serious infections, the answer is uncertain due to its high heterogeneity and possibility of publication bias. More well-designed long-term prospective studies would be important to strengthen these findings.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2017) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: